GlassScriptPhysician profile
Mary W Surman
NPI 1801044284
$4,548.08
in general payments reported to CMS, 2019-2025
31 companies · $908 in 2025
The $908 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $780 · 2022: $1,171 · 2023: $743 · 2024: $945 · 2025: $908.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,596.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $638.38 | 2021-2024 | Belbuca |
| Phathom Pharmaceuticals, INC. | $375.26 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $354.25 | 2021 | |
| Valinor Pharma, LLC | $226.38 | 2023-2024 | Movantik |
| Biohaven Pharmaceutical Holding Company LTD. | $223.18 | 2022 | |
| Neurelis, INC. | $221.33 | 2023-2024 | Valtoco |
| Scilex Pharmaceuticals INC. | $219.80 | 2021-2023 | Ztlido |
| Abbvie INC. | $181.17 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $175.76 | 2024-2025 | |
| Dexcom, INC. | $150.00 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Janssen Biotech, INC. | $146.19 | 2025 | |
| Amgen INC. | $135.00 | 2025 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $123.92 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $121.81 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $112.80 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $112.56 | 2024 | Dupixent |
| Convatec INC. | $110.17 | 2022 | |
| Pfizer INC. | $109.61 | 2023-2024 | |
| Tris Pharma INC | $101.62 | 2024 | Dyanavel Xr |
| Sage Therapeutics, LLC | $100.00 | 2025 | |
| Edwards Lifesciences Corporation | $87.72 | 2025 | |
| Lilly USA, LLC | $86.78 | 2025 | Zepbound |
| Redhill Biopharma INC. | $82.74 | 2022 | |
| Coloplast Corp | $72.84 | 2023 | Altis, Titan |
| Grt US Holding, INC. | $61.99 | 2022 | |
| Mckesson Medical-Surgical, INC. | $58.00 | 2024 | |
| Medtronic, INC. | $54.25 | 2024 | Interstim |
| Arbor Pharmaceuticals, INC. | $38.20 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $37.56 | 2021 | |
| Virtus Pharmaceuticals LLC | $16.10 | 2023 | Levorphanol Tartrate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Surman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.